These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7737035)

  • 1. Pharmacokinetics in the child.
    Crom WR
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):111-7. PubMed ID: 7737035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).
    Knoester PD; Underberg WJ; Beijnen JH
    Anticancer Res; 1993; 13(5C):1795-808. PubMed ID: 8267385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.
    Bouzom F; Walther B
    Fundam Clin Pharmacol; 2008 Dec; 22(6):579-87. PubMed ID: 19049658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific features of pharmacokinetics in children.
    Matalová P; Urbánek K; Anzenbacher P
    Drug Metab Rev; 2016; 48(1):70-9. PubMed ID: 26828377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ontogeny and drug metabolism in newborns.
    Dotta A; Chukhlantseva N
    J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of anticancer drugs in children.
    Crom WR; Glynn-Barnhart AM; Rodman JH; Teresi ME; Kavanagh RE; Christensen ML; Relling MV; Evans WE
    Clin Pharmacokinet; 1987 Mar; 12(3):168-213. PubMed ID: 3555940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic considerations in pediatric pharmacotherapy.
    Lim SY; Pettit RS
    Am J Health Syst Pharm; 2019 Sep; 76(19):1472-1480. PubMed ID: 31532503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.
    Rodman JH; Relling MV; Stewart CF; Synold TW; McLeod H; Kearns C; Stute N; Crom WR; Evans WE
    Semin Oncol; 1993 Feb; 20(1):18-29. PubMed ID: 8475406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of pharmacokinetic limited sampling models for childhood cancer drug development.
    Panetta JC; Iacono LC; Adamson PC; Stewart CF
    Clin Cancer Res; 2003 Nov; 9(14):5068-77. PubMed ID: 14613983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics in infants and children. A reappraisal.
    Kearns GL; Reed MD
    Clin Pharmacokinet; 1989; 17 Suppl 1():29-67. PubMed ID: 2692939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.
    Veal GJ; Cole M; Chinnaswamy G; Sludden J; Jamieson D; Errington J; Malik G; Hill CR; Chamberlain T; Boddy AV
    Eur J Cancer; 2016 Mar; 55():56-64. PubMed ID: 26773420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
    Björkman S
    Br J Clin Pharmacol; 2005 Jun; 59(6):691-704. PubMed ID: 15948934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
    Yu G; Li GF; Markowitz JS
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
    Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of antineoplastic agents in the very young child.
    McLeod HL; Relling MV; Crom WR; Silverstein K; Groom S; Rodman JH; Rivera GK; Crist WM; Evans WE
    Br J Cancer Suppl; 1992 Aug; 18():S23-9. PubMed ID: 1503923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design.
    Rodman JH
    J Adolesc Health; 1994 Dec; 15(8):654-62. PubMed ID: 7696286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development.
    Leeder JS; Meibohm B
    Drug Metab Dispos; 2016 Jul; 44(7):916-23. PubMed ID: 27302933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.